問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

羅榮昇

Recruiting

List

24Cases

2025-01-03 - 2028-12-31

Phase III

Active
MAGNITUDE-2: A phase 3, multinational, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of NTLA-2001 in participants with transthyretin amyloid disease (ATTRv-PN), a hereditary polyneuropathy.

  • Condition/Disease

    Transthyretinopathy with hereditary polyneuropathy (ATTRv-PN)

  • Test Drug

    NTLA-2001

Participate Sites
3Sites

Recruiting3Sites

2025-02-01 - 2027-12-31

Phase II

Completed
A randomized, blinded, placebo-controlled phase 2 trial evaluating the safety, tolerability, quantitative pharmacology, and efficacy (MAGIC) of DNTH103 in adult patients with generalized myasthenia gravis.

  • Condition/Disease

    ● Evaluate the safety and tolerability of DNTH103 in patients with generalized myasthenia gravis (gMG) up to week 13.

  • Test Drug

    DNTH103 150 mg/mL

Participate Sites
8Sites

Recruiting8Sites

2020-12-01 - 2022-11-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting2Sites

Terminated1Sites

2024-12-01 - 2028-01-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-03-01 - 2027-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2024-10-10 - 2026-10-13

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-10-01 - 2031-04-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-05-01 - 2023-10-20

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-05-31 - 2026-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2021-01-01 - 2029-07-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB